Kosmos Energy Ltd. Common Shares (DE) vs Vertex Pharmaceuticals Incorporated — how do they compare? Kosmos Energy Ltd. Common Shares (DE) trades at $2.71 (market cap $1.66B), while Vertex Pharmaceuticals Incorporated trades at $506.07 (market cap $122.98B). The key difference: Vertex Pharmaceuticals Incorporated is far larger — about 74.1× Kosmos Energy Ltd. Common Shares (DE)'s market cap, and Kosmos Energy Ltd. Common Shares (DE) is trading nearer its 52-week high, Vertex Pharmaceuticals Incorporated nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kosmos Energy Ltd. Common Shares (DE) for 0 Days and Vertex Pharmaceuticals Incorporated for 120 Days on average.
| KOS | VRTX | |
|---|---|---|
Market Cap | $1.66B | $122.98B |
Volume | 7,535,344 | 1,155,743 |
Sector | Energy | Health |
52-Week High | $3.27 | $557.96 |
52-Week Low | $0.87 | $407.90 |
Typical Hold Time | 0 Days | 120 Days |
Enterprise Value | $4.30B | $117.11B |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Vertex Pharmaceuticals (VRTX) trades at $498.50, down 1.68% amid mixed technical signals. The stock shows strong fundamentals with $12B revenue, 35% net margins, and robust cash flow. Recent positive Phase 2b data for kidney drug inaxaplin and cystic fibrosis dominance support growth. Technical indicators show bearish momentum with support at $496 and resistance at $512.
Outlook remains positive with 86% analyst buy ratings and $573.50 price target. Key risks include clinical trial outcomes and competitive pressures. The company's expanding pipeline and profitability provide upside potential, though near-term volatility may persist around key technical levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Kosmos Energy Ltd. is a deepwater oil and gas exploration and production company with operations offshore Ghana, Equatorial Guinea, Mauritania, and Senegal in West Africa.
Read more on KOS →Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →